Sensei Biotherapeutics, Inc. (SNSE)
SNSE moved a median of 0.00% 30 minutes after news, and -1.86% by the close. How SNSE actually reacts to news — the realized, point-in-time move the market made, measured across 205 labeled events over the last three years with zero look-ahead.
SNSE’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 34% | 161 |
| 30-min | 0.00% | 45% | 181 |
| 60-min | -0.46% | 43% | 189 |
| to close | -1.86% | 40% | 189 |
| Middle 50% of SNSE reactions | -1.98% to +2.60% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 205 |
Half of all Sensei Biotherapeutics, Inc. news events land between -1.98% and +2.60% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How SNSE reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 21 | -1.33% | 38% | -1.21% |
| Rating reiterations | 18 | +0.97% | 67% | +3.73% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how SNSE ranks against every other measured name →
That’s how SNSE usually reacts — get an email when it moves on news →Email me when SNSE moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to SNSE's baseline. Nothing else.
Recent SNSE events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Sensei Biotherapeutics, For: Jun 10 | SEC filing · Form 8-K | SEC EDGAR | -0.46% | -8.94% | |
| Form EFFECT Sensei Biotherapeutics, | SEC filing · Form EFFECT | SEC EDGAR | -0.46% | -8.94% | |
| Sensei Biotherapeutics Announces Name Change to Faeth Therapeutics, Focused on Advancing PIKTOR, an Oral Therapy Targeting One of the Most Frequently Altered Pathways in Cancer | Press release | Business Wire | -0.46% | -8.94% | |
| Form 8-K Sensei Biotherapeutics, For: Jun 10 | SEC filing · Form 8-K | SEC EDGAR | -7.84% | -18.69% | |
| Form S-3/A Sensei Biotherapeutics, | SEC filing · Form S-3 | SEC EDGAR | -7.84% | -18.69% | |
| Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | — | -9.96% | |
| Form 10-K/A Sensei Biotherapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.24% | -21.68% | |
| Form S-3/A Sensei Biotherapeutics, | SEC filing · Form S-3 | SEC EDGAR | +0.24% | -21.68% | |
| Form 8-K Sensei Biotherapeutics, For: May 22 | SEC filing · Form 8-K | SEC EDGAR | — | -3.85% | |
| Form DEFA14A Sensei Biotherapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | — | -3.85% | |
| Form 8-K Sensei Biotherapeutics, For: May 21 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -3.68% | |
| Form DEFA14A Sensei Biotherapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | +0.00% | -3.68% | |
| Form 10-Q Sensei Biotherapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +4.24% | |
| Form 8-K Sensei Biotherapeutics, For: May 15 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +4.24% | |
| Form S-8 Sensei Biotherapeutics, | SEC filing · Form S-8 | SEC EDGAR | +0.00% | +4.24% | |
| Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | Press release | Business Wire | +0.00% | +4.24% | |
| Sensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast Cancer | Press release | Business Wire | +0.00% | -6.64% | |
| Form S-3 Sensei Biotherapeutics, | SEC filing · Form S-3 | SEC EDGAR | +0.00% | -5.88% | |
| Form ARS Sensei Biotherapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.00% | -5.88% | |
| Form DEF 14A Sensei Biotherapeutics, For: Jun 10 | SEC filing · Form DEF | SEC EDGAR | +0.00% | -5.88% | |
| Form DEFA14A Sensei Biotherapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | +0.00% | -5.88% | |
| Form 8-K Sensei Biotherapeutics, For: Apr 10 | SEC filing · Form 8-K | SEC EDGAR | +3.92% | +5.72% | |
| Form PRE 14A Sensei Biotherapeutics, For: Jun 10 | SEC filing · Form PRE | SEC EDGAR | +3.92% | +5.72% | |
| Form 8-K/A Sensei Biotherapeutics, For: Feb 17 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.41% | |
| Sensei Biotherapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference | Press release | Business Wire | +0.00% | -3.08% | |
| Form 10-K Sensei Biotherapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +9.89% | +31.83% | |
| Form 8-K Sensei Biotherapeutics, For: Mar 30 | SEC filing · Form 8-K | SEC EDGAR | -0.35% | -6.58% | |
| Sensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update | Press release | Business Wire | -0.35% | -6.58% | |
| Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | +2.03% | +0.07% | |
| Form D Sensei Biotherapeutics, | SEC filing · Form D | SEC EDGAR | +0.13% | +2.71% | |
| Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | -2.04% | -5.57% | |
| Form 8-K Sensei Biotherapeutics, For: Feb 17 | SEC filing · Form 8-K | SEC EDGAR | -4.64% | -5.51% | |
| Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement | Press release | Business Wire | -4.64% | -5.51% | |
| Form 8-K Sensei Biotherapeutics, For: Feb 13 | SEC filing · Form 8-K | SEC EDGAR | +0.11% | +0.33% | |
| Egle Therapeutics Appoints John Celebi as Chief Executive Officer | Press release | GlobeNewswire | +0.00% | +7.78% | |
| Form 8-K Sensei Biotherapeutics, For: Dec 22 | SEC filing · Form 8-K | SEC EDGAR | — | +1.09% | |
| Form 10-Q Sensei Biotherapeutics, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | — | -10.76% | |
| Form 8-K Sensei Biotherapeutics, For: Nov 14 | SEC filing · Form 8-K | SEC EDGAR | — | -10.76% | |
| Sensei Biotherapeutics Reports Third Quarter 2025 Financial Results | Press release | GlobeNewswire | — | -10.76% | |
| Form 8-K Sensei Biotherapeutics, For: Oct 30 | SEC filing · Form 8-K | SEC EDGAR | +8.77% | -17.06% | |
| Sensei Biotherapeutics Announces Initiation of Strategic Review to Maximize Shareholder Value | Press release | GlobeNewswire | +8.77% | -17.06% | |
| Form 8-K Sensei Biotherapeutics, For: Oct 17 | SEC filing · Form 8-K | SEC EDGAR | +9.73% | -22.26% | |
| Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025 | Press release | GlobeNewswire | +9.73% | -22.26% | |
| Sensei Biotherapeutics to Host Virtual KOL Event to Discuss Full Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors on October 20, 2025 | Press release | GlobeNewswire | -0.11% | +1.22% | |
| Sensei Biotherapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference | Press release | GlobeNewswire | +0.00% | +9.32% | |
| Form 10-Q Sensei Biotherapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -5.95% | |
| Form 8-K Sensei Biotherapeutics, For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | — | -2.84% | |
| Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | — | -2.84% | |
| Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025 | Press release | GlobeNewswire | — | +6.41% | |
| Form 8-K Sensei Biotherapeutics, For: Jul 02 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -0.55% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the SNSE section they belong to.
Where else SNSE is measured.
SNSE earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Sensei Biotherapeutics, Inc.'s median reaction calculated?
Every labeled SNSE news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 205 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 45% of SNSE's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does SNSE's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.